Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura
Phase II Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura
Sponsor: Hematology and Oncology Specialists
This PHASE2 trial investigates Autoimmune Thrombocytopenic Purpura and is currently ongoing. Hematology and Oncology Specialists leads this study, which shows 5 recorded versions since 2001 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Sep 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hematology and Oncology Specialists
For direct contact, visit the study record on ClinicalTrials.gov .